Session » Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 451

A Matrix Risk Model for Prediction of Radiographic Progression in Early Rheumatoid Arthritis Based on Treatment Response at 3 Months

9:00AM-11:00AM: Abstract Number: 419

Abatacept Initiation in Chilean Patients with Long Lasting Rheumatoid Arthritis. Hospital Padre Hurtado Experience

9:00AM-11:00AM: Abstract Number: 462

ABP 710: Matching Critical Biological Functions with Infliximab

9:00AM-11:00AM: Abstract Number: 432

ACPA and RF As Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 461

Additions to Methotrexate with Conventional and Biologic Dmards in Rheumatoid Arthritis: Are There Differences in Subsequent Time to Treatment Failure?

9:00AM-11:00AM: Abstract Number: 409

An Evaluation of Absolute Neutrophil Count As a Biomarker of Inflammatory and Clinical Disease Activity in Baricitinib-Treated Patients

9:00AM-11:00AM: Abstract Number: 455

Analysis of Real-World Treatment Patterns in a Matched Sample of Rheumatology Patients with Continuous Infliximab Therapy or Switched to Biosimilar Infliximab

9:00AM-11:00AM: Abstract Number: 439

Analysis of Rheumatoid Arthritis Patients That Did Not Achieve the Treatment Goal By the Treat-to-Target Strategy in Daily Practice

9:00AM-11:00AM: Abstract Number: 410

Association between Anti-Citrullinated Protein Antibody Status and the Incidence of Erosive Disease in Patients with RA

9:00AM-11:00AM: Abstract Number: 415

Baricitinib Reduces GlycA Levels in Phase 2 and Phase 3 Clinical Trials in Patients with Moderate to Severe Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 436

Baseline Anemia As a Predictor of Radiographic Progression in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analyses from Two Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 412

Baseline Values for Plantar Pressure and Background Characteristics As Indicators for the Limit of Conservative Treatment of Rheumatoid Forefoot Deformity

9:00AM-11:00AM: Abstract Number: 465

Basement Membrane Remodeling in Rheumatoid Arthritis Associates with Disease Activity, Response to IL-6 Inhibitor Treatment and Radiographic Progression: Analysis of Two Phase III Clinical Trials

9:00AM-11:00AM: Abstract Number: 463

Certolizumab Pegol for Fatigue in Chronic Inflammatory Rheumatic Diseases: A Meta-Analysis

9:00AM-11:00AM: Abstract Number: 435

Characteristics of Rheumatoid Arthritis Patients Who Have a DMARD Interruption and the Impact of Using a Bridging Medication on Clinical and Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 470

Clinical Response to the First Biologic in Rheumatoid Arthritis Patients with Moderate Disease in a Real World Clinical Cohort

9:00AM-11:00AM: Abstract Number: 474

Comparison of Tofacitinib Efficacy in Patients with Moderate Vs Severe Rheumatoid Arthritis: Pooled Analysis of Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 459

Disease Course in Seronegative RA Patients Classified According to the 2010 ACR/EULAR Criteria

9:00AM-11:00AM: Abstract Number: 450

Disease Duration and Withdrawal of Biologic Agents Predict Radiological Progression in a Cohort of Rheumatoid Arthritis Patients in Latin America. a Real World Study

9:00AM-11:00AM: Abstract Number: 444

Do Rheumatoid Arthritis Clinical Disease Activity Index Based Treat-to-Target Treatment Decisions Always Correspond to Usual Care Treatment Decisions at Point of Care?

9:00AM-11:00AM: Abstract Number: 427

Do We Treat Men and Women Differently, and Is This a Good Thing?

9:00AM-11:00AM: Abstract Number: 442

Early Treatment with Hydroxychloroquine Is Associated with Better Long-Term Outcomes in a Group of Hispanic Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 413

Economic Burden Associated with Anti-Cyclic Citrullinated Peptide Antibody Positivity in Patients Newly Diagnosed with RA

9:00AM-11:00AM: Abstract Number: 469

Effect of Patient Involvement in Treatment Decision Making on Disease Outcomes in Rheumatoid Arthritis in the USA

9:00AM-11:00AM: Abstract Number: 425

Efficacy of Monotherapy of the Biologic Dmards in Patients with Rheumatoid Arthritis: Real Life Data from the Hong Kong Biologics Registry

9:00AM-11:00AM: Abstract Number: 418

Exploratory Analysis to Identify Factors Associated with Risk of Structural Progression, Defined As Change from Baseline

9:00AM-11:00AM: Abstract Number: 434

Factors Associated with Treatment Adherence in Rheumatoid Arthritis: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 411

Factors That Drive Treatment Recommendation during Rheumatoid Arthritis Patient´s Follow-up, Differ According to Physician Experience

9:00AM-11:00AM: Abstract Number: 445

FLARE-RA Instrument Detects RA Flares Independent of Disease Activity

9:00AM-11:00AM: Abstract Number: 438

High Multi-Biomarker Disease Activity Score Is Associated with High Risk of Radiographic Progression in Six Cohorts

9:00AM-11:00AM: Abstract Number: 428

Impact of Smoking Cessstion Advise in Patients with Rheumatoid Arthritis to Help Quit Smoking

9:00AM-11:00AM: Abstract Number: 430

Implementation of a Treat-to-Target Remission Strategy for Rheumatoid Arthritis in Australian Public and Private Rheumatology Clinics – Identification of Clinician and Patient Barriers

9:00AM-11:00AM: Abstract Number: 417

Improvement in Overall Work Productivity Among Biologic-NaïVe Patients with Rheumatoid Arthritis Treated with Tocilizumab Subcutaneous Injection: A Prospective, Real World, Observational Study in Japan

9:00AM-11:00AM: Abstract Number: 458

Improving Knowledge of Rheumatoid Arthritis Clinical Trial Results Among Rheumatologists: Effect of an Online Educational Intervention

9:00AM-11:00AM: Abstract Number: 468

Initiation of Biologic Disease Modifying Antirheumatic Drug Therapy and Associated Changes in Disease Activity Measures in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort

9:00AM-11:00AM: Abstract Number: 457

Levels of Satisfaction with RA Treatment and Associated Alignment between Rheumatologists and Their Patients across Latin America

9:00AM-11:00AM: Abstract Number: 420

Machine Learning in Rheumatology: Development and Validation of a Predictive Model for Rheumatoid Arthritis Mortality Using Random Survival Forests

9:00AM-11:00AM: Abstract Number: 449

Medical Bugs for Pain Relief in Patients with Rheumatoid Arthritis, a Systematic Review

9:00AM-11:00AM: Abstract Number: 473

Medication Utilization Patterns of Rheumatoid Arthritis Patients Receiving Anti-TNF Infusion in Community Rheumatology Practices in the United States: Will Differences in Dosing and Administration Efficiencies between Intravenous Golimumab and Infliximab Have a Cost Impact for Payers?

9:00AM-11:00AM: Abstract Number: 443

Methotrexate Treatment Strategies in an Early Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 446

Methotrexate Use and Fatigue in Rheumatoid Arthritis Patients: Results from a National Patient Registry

9:00AM-11:00AM: Abstract Number: 414

Multi-Biomarker Disease Activity and Autoantibody Status Lead to Cost Effective Tapering Algorithms in Rheumatoid Arthritis Patients in Sustained Remission

9:00AM-11:00AM: Abstract Number: 422

No Added Predictive Value of Serum Calprotectin for Treatment Response to Adalimumab or Etanercept in RA Patients

9:00AM-11:00AM: Abstract Number: 466

Plasma Cytokines at Diagnosis May Predict Non-Response to Methotrexate in Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 431

Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis: An Interim Report of Safety Data

9:00AM-11:00AM: Abstract Number: 448

Predicting Remission at 6 Months in Early Rheumatoid Arthritis Treated with Conventional Synthetic Dmards

9:00AM-11:00AM: Abstract Number: 433

Predictors of Earlier Biologic Initiation Among Patients with Rheumatoid Arthritis Starting Methotrexate

9:00AM-11:00AM: Abstract Number: 424

Re-Establishment of Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in Rheumatoid Arthritis Patients after Temporary Discontinuation

9:00AM-11:00AM: Abstract Number: 437

Recruitment of RA Trials in the Modern Era: Are United States-Based Trials Still Feasible?

9:00AM-11:00AM: Abstract Number: 423

Refractory Pain in Spite of Inflammation Control after Start of Anti-TNF Therapy in RA: Observational Data from Southern Sweden

9:00AM-11:00AM: Abstract Number: 429

Repair of Joint Damage Is Rare in Newly Diagnosed Rheumatoid Arthritis Patients and Appears Not to Relate to Previous Suppression of Inflammation

9:00AM-11:00AM: Abstract Number: 475

Rheumatoid Arthritis Patient Characteristics Also Predict Response to Therapy with Biologic Agents: Results from the Corrona Certain Study

9:00AM-11:00AM: Abstract Number: 440

Rheumatoid Arthritis Patient´s Journey: Delay in Diagnosis and Treatment

9:00AM-11:00AM: Abstract Number: 471

Rheumatoid Arthritis Patients Resistant to Biologic Therapy, Are They Different?

9:00AM-11:00AM: Abstract Number: 421

Serum Calprotectin Is Not Predictive for Successful Dose Reduction or Discontinuation of TNF Inhibitors in RA Patients with Low Disease Activity

9:00AM-11:00AM: Abstract Number: 426

Serum Levels of the Anti-TNF Biologics Correlate with Clinical Efficacy in Patients with Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 467

Smoking and Opioid Use Is Associated with Symptom Severity in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 441

Social Media Based, Direct-to-Patient Study Designed for Development of “from Home” Testing for Rheumatoid Arthritis Patients Is Feasible and Engaged Individuals with Distinct Clinical Characteristics

9:00AM-11:00AM: Abstract Number: 454

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Correlates with Disease Activity in Early Rheumatoid Arthritis and Reflects Joint Damage over Time

9:00AM-11:00AM: Abstract Number: 416

The Impact of Therapy on Anti-Carbamylated Protein Antibody Isotypes and Serostatus in Patients with Early RA Treated with Abatacept and MTX

9:00AM-11:00AM: Abstract Number: 453

The Therapy with Tocilizumab Is Not Associated with Periarticular Demineralisation and Finger Joint Space Narrowing in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 456

Time from First Symptom Onset to First Advanced Therapy Amongst RA Patients in Latin America

9:00AM-11:00AM: Abstract Number: 452

Time to First Treatment Is Associated with a Refractory Course of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 447

Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 460

Usefullness of Serum Angiogenic and Proinflammatory Cytokines to Discriminate between 6 Sets of Remission Criteria and Biomarkers of Radiographic Progression and Clinical Flare in RA in Clinical Remission. Pre-Eliminary Results of a Study of 5 Years of Follow-up

9:00AM-11:00AM: Abstract Number: 464

Value of Matrix Metalloproteinase-3 Regarding Prediction for Joint Destruction at 1 Year Is Different between Sexes in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 472

Viral Hepatitis Influences Patient Reported Outcomes Measures in Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].